In:
Clinical and Experimental Pharmacology and Physiology, Wiley, Vol. 44, No. 9 ( 2017-09), p. 914-923
Abstract:
Some biomarkers play important roles in the endothelial dysfunction of patients with pulmonary arterial hypertension ( PAH ), including nitric oxide ( NO ), endothelin‐1 ( ET ‐1), asymmetric dimethylarginine ( ADMA ), galectin‐3 (Gal‐3), B‐type natriuretic peptide ( BNP ), and uric acid ( UA ). However, studies on these biomarkers in pulmonary artery blood in congenital heart disease‐ PAH ( CHD ‐ PAH ) and the effect of iloprost on the regulation of biomarkers are lacking. This study investigated potential CHD ‐ PAH biomarkers and their association with the severity of disease. The effect of iloprost on the regulation of these biomarkers was also studied. A total of 31 patients with CHD ‐ PAH were enrolled. Seven with positive effects of iloprost (the average reduction in mPAP 11.13±1.73 mm Hg) and 19 with negative effects of iloprost (the average reduction in mPAP 4.21±4.87 mm Hg; iloprost positive group [ IPG ] vs iloprost negative group [ ING ], P 〈 .01) and five age‐matched controls were studied. The pulmonary artery blood sample was collected before and after inhaling iloprost, and the plasma concentrations of Gal‐3, ADMA , ET ‐1, and NO were measured. A significant positive linear relationship was observed between mPAP and plasma ET ‐1, BNP , ADMA , and UA levels in all patients with CHD ‐ PAH . ET ‐1, ADMA , BNP , and UA levels had a significant linear relationship with mean pulmonary arterial pressure, which could be used to predict the severity of CHD ‐ PAH . ET ‐1 might be a potential biomarker to pre‐evaluate the effect of iloprost on CHD ‐ PAH . Iloprost could affect the expression of Gal‐3 and, therefore, the process of fibrosis could be influenced by iloprost.
Type of Medium:
Online Resource
ISSN:
0305-1870
,
1440-1681
DOI:
10.1111/cep.2017.44.issue-9
DOI:
10.1111/1440-1681.12796
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
2020033-X
SSG:
15,3
Permalink
